Mark E. Cooper AO, MB BS, PhD, FRACP, FAHMSHead, Diabetes Department, Central Clinical School, Monash University, Melbourne, Australia
Dr. Mark Cooper is the inaugural Head of the Department of Diabetes, Central Clinical School, Monash University. He was previously the Chief Scientific Officer of the Baker IDI Heart & Diabetes Institute as well as the Director of the Juvenile Diabetes Research Foundation Centre(JDRF) for Diabetes Complications. He is a trained endocrinologist with an appointment at the co-located Alfred Hospital.
Dr. Cooper studied medicine at the University of Melbourne and then completed his physicians training at the Austin Hospital as well as his PhD under Dr. George Jerums and Professor Austin Doyle in the University of Melbourne, Department of Medicine, Austin Hospital.
Dr. Cooper has successfully competed for a large number of peer reviewed grants over the last 15 years from a range of organizations including not only JDRF but also the National Health & Medical Research Council of Australia, National Institutes of Health, National Heart Foundation of Australia, Diabetes Australia and Kidney Health Australia. In 1999, Dr. Cooper was awarded the Eric Susman prize from the Royal Australasian College of Physicians for his research in the field of renal and vascular complications of diabetes. In 2005, he was awarded the Australian Diabetes Society (ADS) Kellion Award for outstanding contribution to diabetes research in Australia. In 1999, he was awarded a Centre Grant from JDRF which was subsequently renewed in 2003. He is a previous recipient of a scholars award from the JDRF. This work was further supported by a 5 year Australia Fellowship awarded by NHMRC in 2009.
Dr. Cooper is currently Co-Chair of the JDRF Medical Science Review Committee (Complications Panel). He is regularly invited to international meetings and has more than 500 peer reviewed publications. He was the 2016 recipient of the Claude Bernard Award from the European Association for the Study of Diabetes and in 2017 the Edwin Bierman Award from the American Diabetes Association. He received an Order of Australia (Officer) in 2017.
Dr cooper has received grants and Le tire fees from Novo-Nordisk, Boehringe-Ingelheim and AstraZeneca, who produce GLP1 receptor agonists and SGLT2 inhibitors.